Otsuka Preps for July Decision on Centanafadine for ADHD

Why It Matters

Centanafidine could expand non‑stimulant treatment options and capture a sizable share of a growing ADHD market, reshaping prescribing patterns and Otsuka’s revenue profile.

Key Takeaways

• FDA set July 24 decision for centanafidine.
• First norepinephrine‑dopamine‑serotonin reuptake inhibitor for ADHD.
• Phase 3 trials showed significant symptom improvement.
• Potential peak sales $650 million in Japan.
• Adds non‑stimulant option amid growing adult ADHD diagnoses.

Pulse Analysis

The United States now sees roughly 7 million children and 15.5 million adults living with ADHD, a prevalence that has surged as social media awareness reduces stigma and clinicians recognize adult presentations. While stimulant medicines dominate prescriptions, concerns over cardiovascular effects, insomnia, and abuse have driven insurers and patients to seek alternatives. Non‑stimulant therapies such as Sage’s Qelbree have begun to capture market share, yet the segment remains fragmented. This environment creates a fertile ground for innovative agents that can address the full spectrum of attention, hyperactivity, and impulsivity without the typical stimulant drawbacks.

Centanafidine, Otsuka’s triple‑acting norepinephrine‑dopamine‑serotonin reuptake inhibitor (NDSRI), positions itself as the first drug of its class for ADHD. Four phase 3 trials across children, adolescents, and adults reported statistically significant improvements on the ADHD‑RS‑5 and AISRS scales, with a safety profile that mitigates insomnia and shows low abuse potential. The oral, once‑daily formulation simplifies adherence compared with multi‑dose regimens. By targeting three neurotransmitter pathways simultaneously, centanafidine aims to provide broader symptom control, a claim that could differentiate it from selective norepinephrine reuptake inhibitors and traditional stimulants.

The FDA’s priority review, targeting a July 24 decision, underscores the agency’s confidence in the data and the unmet need for non‑stimulant options. Otsuka projects a peak market opportunity of roughly ¥100 billion ($650 million), a figure that rivals early sales trajectories of Qelbree and could reshape the competitive landscape. Success would also reinforce Otsuka’s late‑stage pipeline momentum, which recently delivered approvals for Voyxact and Dawnzera. Investors are likely to view centanafidine as a catalyst for revenue diversification, while clinicians may finally have a truly first‑in‑class NDSRI to broaden therapeutic choices for diverse ADHD phenotypes.